Roundtable Discussions
In the eighth and final segment of this roundtable series, the panel discusses future directions in the field of NSCLC.
In the seventh segment of this roundtable series, the panel discusses how path CR affects postoperative management.
In the sixth segment of this roundtable series, the panel discusses neoadjuvant versus perioperative approaches.
Perioperative Immunotherapy in NSCLC: Evolving Data, Surgical Planning, and Real-World Collaboration
In the fifth segment of this roundtable series, the panel discusses CheckMate 77T, CheckMate 816, and more. 
In the fourth segment of this roundtable series, the panel discusses multidisciplinary, comprehensive collaboration.
In the eighth part of this roundtable series, the panel discusses how to minimize the risk of NSCLC recurrence after surgery.
In the second segment of this roundtable series, the panel discusses the importance of safe sampling in biomarker testing.
In the first segment of this roundtable series, the panel discusses the initial steps in NSCLC diagnosis and treatment.
Experts weigh in on the long-term results presented at the 2024 American Society of Clinical Oncology Annual Meeting.
The panel discusses key questions about NSCLC treatment regimens and the research that could answer them.
Experts discuss important management considerations and the importance of working with a multidisciplinary team.
A panel of experts shares their insights on key developments and advances in lung cancer treatment research.
An expert panel discusses treatment and quality-of-life considerations, as well as what to do while awaiting NGS results.
The panel discusses combination therapies and treatment considerations for patients without targetable mutations.
Experts weigh in on unmet needs and what clinicians should consider when treating patients who lack driver mutations.
Experts weigh in on NSCLC screening and diagnostic challenges and the prevalence of metastatic disease at diagnosis.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.